Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis.
Tirzepatide 與有無糖尿病個體的癌症風險:系統性回顧與統合分析。
Endocrinol Metab (Seoul) 2025-01-15
Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.
Tirzepatide(胰臟炎和膽囊或膽道疾病)在2型糖尿病和肥胖中的安全問題:系統回顧和荟萃分析。
Front Endocrinol (Lausanne) 2024-03-29
Evaluating the Efficacy and Safety of Tirzepatide on Glycaemic and Non-glycaemic Outcomes in Diabetes: A Systematic Review of Meta-Analyses.
評估 Tirzepatide 在糖尿病患者中對血糖和非血糖結果的療效和安全性:對 Meta 分析的系統性回顧。
Cureus 2024-04-27
Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Tirzepatide在2型糖尿病患者中的使用與癌症風險:隨機對照試驗的荟萃分析。
Diabetes Res Clin Pract 2024-06-26
Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials.
tirzepatide 與安慰劑在無糖尿病的超重或肥胖成人中的療效與安全性:隨機對照試驗的系統評價與統合分析。
Int J Clin Pharm 2024-07-22
The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database.
tirzepatide 的真實世界安全性概況:FDA 不良事件報告系統 (FAERS) 數據庫的藥物監測分析。
J Endocrinol Invest 2024-08-14
Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials.
Tirzepatide 在管理 2 型糖尿病方面優於長效胰島素:三項第三期隨機對照試驗的 meta-analysis。
Int J Obes (Lond) 2024-08-29
Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis.
在無糖尿病的超重或肥胖成人中,使用GLP-1 RAs或雙重GIP/GLP-1受體激動劑tirzepatide治療的重大不良心血管事件及全因死亡風險:系統性回顧與荟萃分析。
Ther Adv Neurol Disord 2024-09-30
這項研究系統性回顧了16項隨機對照試驗,分析了胰高血糖素樣肽-1受體激動劑(GLP-1 RAs)及雙重GIP/GLP-1 RA tirzepatide在沒有糖尿病的超重或肥胖成人中的心血管及神經保護效果。結果顯示,這些藥物顯著降低重大不良心血管事件(MACE)和全因死亡率的風險,MACE發生率降低至0.79,全因死亡率降至0.80。雖然心血管死亡率有下降趨勢,但未達顯著性。研究建議需進一步探討其對中風的神經保護效果。
PubMedDOI
Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis.
新型雙重激素 Tirzepatide(GIP/GLP-1 受體激動劑)作為非糖尿病個體的抗肥胖藥物的療效與安全性:系統性回顧與統合分析。
touchREV Endocrinol 2024-11-11
Once-weekly tirzepatide versus once-daily basal insulin in managing type 2 diabetes inadequately controlled with oral anti-hyperglycemic drugs: a systematic review and meta-analysis.
每週一次的 tirzepatide 與每日一次的基礎胰島素在口服降血糖藥物控制不佳的 2 型糖尿病管理中的比較:系統性回顧與統合分析。
Endocr Pract 2024-12-13
Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta-Analysis.
Tirzepatide 的胰臟安全性及其對胰島素細胞功能的影響:系統性回顧與統合分析。
Obes Sci Pract 2024-12-25